Most buyers of Indian generic medicines never look at clinical trial evidence — and that is precisely where quality expectations are quietly set. Every product you source was, at some point, an investigational new drug whose safety was established in an approved trial under the New Drugs and Clinical Trials Rules, 2019 and the oversight of the Central Drugs Standard Control Organisation (CDSCO). Understanding how that approval is granted, and what the public record actually shows, gives you a far better read on a manufacturer’s scientific discipline than any brochure claim.
This guide explains the CDSCO clinical trial approval pathway in plain language, decodes the documents you can actually check from outside India, and closes with a practical framework for using trial evidence in supplier due diligence. It is written for international buyers, importers, and procurement teams who need to judge Indian pharmaceutical suppliers on verifiable evidence rather than marketing.
🏛️ Why Clinical Trial Evidence Belongs in Your Buyer Checklist
India supplies a large share of the world’s generic medicines, and the regulatory logic underpinning that supply is cumulative: a manufacturer’s ability to run and document a clinical trial properly is the same organisational muscle that produces a defensible batch record. A facility that cannot manage protocol amendments, informed consent documentation, and adverse event reporting is unlikely to manage deviation handling and data integrity well either.
There is a second, more immediate reason. India is actively reshaping its clinical research framework. As reported by The Economic Times in November 2026, the government has begun informal discussions on allowing multinational pharmaceutical companies to conduct first-in-human (FIH) Phase I trials in India for molecules discovered outside the country — a change that would extend the existing framework for Indian-origin molecules to global sponsors. The same reporting notes that having India-generated Phase I data can shorten new-product approval timelines, against a lag of two years or more for regulatory review of dossiers submitted without local early-phase data.
That is a significant shift in the evidence base available on Indian manufacturers. Buyers who understand how trial approvals are documented will be able to read that emerging evidence directly instead of relying on third-party summaries.
📋 The Legal Architecture: NDCT Rules 2019 and the 2026 Amendments
Clinical trials in India are governed by the New Drugs and Clinical Trials Rules, 2019, framed under the Drugs and Cosmetics Act, 1940. The Rules cover approval of new drugs, conduct of clinical trials for drugs developed in India and abroad, participation of Indian sites in global trials, bioavailability (BA) and bioequivalence (BE) studies, manufacturing of investigational products, and registration and oversight of Ethics Committees.
In January 2026, the Ministry of Health and Family Welfare notified the New Drugs and Clinical Trials (Amendment) Rules, 2026. The changes most relevant to a buyer’s reading of the record are:
- A prior-intimation pathway under Rule 52. For specified lower-risk categories, applicants may file an online Form CT-10 as prior intimation and begin manufacturing for analytical or non-clinical testing upon acknowledgment, instead of waiting for formal manufacturing permission. High-risk categories remain excluded — sex hormones, cytotoxic drugs, beta-lactam antibiotics, biologics containing live microorganisms, and narcotic or psychotropic substances.
- Review timelines cut from 90 to 45 working days for Rule 53 (manufacturing permission for new drugs and investigational new drugs) and Rule 60 (manufacture of unapproved active pharmaceutical ingredients for development).
- Harmonised terminology across Rules 52 to 66, drawing a clear legal distinction between “permission” and “acknowledgment of prior intimation” — with conditions on manufacturing, GMP, record-keeping, labelling, suspension, cancellation, and appeal.
- Retained oversight. Amended Rules 58 and 62 preserve the Central Licensing Authority’s power to suspend a manufacturing permission, cancel an acknowledgment of prior intimation, issue show-cause notices, and allow structured appeal to the Central Government.
The practical consequence for buyers: a 45-day statutory clock is a floor on speed, not a substitute for evidence. When you see a recent clinical trial authorisation, the useful question is not how fast it was granted but whether the documentation trail is complete and internally consistent.
🔍 The Approval Pathway, Decoded Step by Step
Step 1 — Regulatory classification. Determine whether the product is a new drug, an investigational new drug, a fixed-dose combination, a biosimilar, or a BA/BE study. The classification determines which rules and which forms apply, and therefore which evidence should exist.
Step 2 — Ethics Committee review. No trial proceeds without approval from a registered Ethics Committee. Under the 2019 framework, Ethics Committees must be registered with the Central Licensing Authority, and their registration status is a checkable fact rather than a claim. In May 2026, ICMR also released operational guidelines for a single ethics review of multicentre research, aimed at harmonising review across participating institutions.
Step 3 — Application through the SUGAM portal. Applications are filed electronically, which means submission dates, query cycles, and response timelines are system-recorded. Review is conducted by CDSCO, with Subject Expert Committees (SECs) advising on investigational new drugs, cell and gene therapies, and oncology. Economic Times reporting in November 2026 noted that 21 external experts with drug-development experience are already participating in SEC discussions.
Step 4 — Central Licensing Authority decision. The CLA grants permission, seeks clarification, or rejects. For products developed outside India, current rules require available foreign clinical data — including Phase I data — to be submitted with the application before any repeat Phase I, or Phase II and Phase III trials, may be permitted in India.
Step 5 — Conditions and post-approval obligations. An approval is not a clean bill of health. It carries conditions on protocol conduct, safety reporting, record retention, and, where applicable, the requirement to report serious adverse events within defined timelines. Compliance with those conditions is what the record shows over time.
📊 What the Public Record Actually Shows — and Where to Find It
The good news for an international buyer is that a meaningful share of the CDSCO trial record is published. Three document families are worth knowing:
- Subject Expert Committee recommendations. CDSCO publishes SEC recommendation documents for Investigational New Drugs meetings, typically as dated PDFs naming the meeting number and the products discussed. These show the committee’s reasoning — including conditions imposed and clarifications sought — and are the single most informative public artefact for judging how a product’s evidence was received.
- New drug approval and clinical trial permission records referenced in CDSCO’s published communications, which establish that permission exists and when it was granted.
- The trial’s own registration entry, which should be consistent with the regulator’s published record on sponsor identity, indication, phase, and site locations.
A useful discipline when reading these documents: check for internal consistency rather than for completeness. Does the sponsor name match the applicant name on the licence? Does the indication in the SEC recommendation match the indication on the manufacturer’s website? Does the phase described publicly match the phase the committee discussed? Divergence in any of these is a legitimate question for a supplier — not an accusation, but a documented query.
⚠️ One caution on dates. CDSCO’s document repository is organised by upload path and meeting date, and older links are frequently reorganised. If a link you saved returns an error months later, that is a filing change rather than evidence that the approval was withdrawn. Confirm withdrawal only through an explicit CDSCO order or a published cancellation, never through a broken link.
🧪 The Wider Reform Context: What Is Under Discussion vs What Is Notified
This distinction matters enormously for anyone citing Indian regulatory change in a procurement decision. As of mid-November 2026, the following are notified and in force:
- The New Drugs and Clinical Trials (Amendment) Rules, 2026, notified in January 2026 — prior intimation under Rule 52, the 45-day review timelines, harmonised permission/intimation language, and retained suspension powers.
- Revised Schedule M good manufacturing practices, under tighter enforcement through 2026. Economic Times reported in November 2026 that of roughly 8,000 units on the regulator’s records, more than 1,400 have been audited so far, with outcomes ranging from licence cancellations to improvement notices and remediation orders.
- ICMR’s Delphi study, Advancing First-in-Human Phase 1 Clinical Trials in India, released 20 May 2026 at the first ICMR Annual Clinical Trial Meet, developed through two consultation rounds with 37 experts from industry, CROs, academia, and regulatory agencies, alongside operational guidelines for single ethics review of multicentre research.
- The Bio Pharma Shakti programme announced in the Union Budget 2026–27, envisaging ₹10,000 crore over five years, including a proposed national network of 1,000 accredited clinical trial sites, three additional National Institutes of Pharmaceutical Education and Research, and upgrades to seven existing institutes.
The following are under discussion only, with no notified amendment:
- Allowing multinational companies to conduct first-in-human Phase I trials on foreign-discovered molecules. Government officials quoted by Economic Times confirm informal discussions have started and that “there is a demand from international companies,” while noting a formal decision would require the entire process and safeguards to be worked out.
- Application for Pharmaceutical Inspection Co-operation Scheme (PIC/S) membership — processes initiated, with officials estimating a six-to-seven-year horizon.
- Movement from observer status to the core group of the International Council for Harmonisation (ICH), estimated at 18 months to two years.
- A proposed 1,500-person regulatory workforce expansion, described by officials as being in the final stage of approval, with hiring possibly beginning within three months.
If a supplier cites any item in the second list as a current advantage, treat it as forward-looking rather than factual. The first list is where verifiable compliance sits today.
✅ A Practical Buying Framework: Six Checks on Trial Evidence
- Confirm the regulatory classification. Ask the supplier to state, in writing, whether the product was approved as a new drug, a generic requiring BA/BE only, a biosimilar, or a fixed-dose combination. The answer determines what evidence should exist.
- Request the SEC recommendation reference. For any product with an investigational new drug history, the SEC meeting number and date are specific, checkable identifiers. A supplier who cannot produce one for a genuinely novel product has a gap.
- Verify Ethics Committee registration. The committee that reviewed the trial should be traceable to a registration with the Central Licensing Authority, not merely named in a document.
- Cross-check sponsor identity. The entity named as sponsor in the trial record should match the entity holding the manufacturing licence, or the relationship should be documented. Unexplained third-party sponsors are a red flag in due diligence.
- Read the conditions, not just the approval. A permission with unresolved conditions on stability data, dissolution specifications, or site inspection is materially different from one with conditions closed out. Asking which conditions remain open is one of the highest-value questions a buyer can ask.
- Separate GMP evidence from trial evidence. A clean clinical trial record and a clean GMP inspection record are different artefacts produced by different functions. A strong trial history does not substitute for a current Schedule M compliance status, and vice versa. Verify both.
❓ Frequently Asked Questions
Does a CDSCO trial approval mean the drug is approved for sale?
No. A clinical trial permission authorises the conduct of a study, not the marketing of a product. Marketing requires a separate new drug approval or, for generics, the appropriate manufacturing and product permissions. Confusing the two is one of the most common misreadings of Indian regulatory documents.
Can I rely on a two-year-old SEC recommendation document?
As evidence of what the committee concluded at that meeting, yes. As evidence of current status, no. Conditions may have been closed, additional data may have been requested, or the programme may have been discontinued. Treat historical documents as history and ask for current status explicitly.
Is the NDCT 2026 amendment relevant to generic medicine buyers?
Indirectly, and more than it appears. The 45-day review timeline and the prior-intimation pathway shorten development cycles for the manufacturers you buy from, which affects how quickly new formulations reach the market. Your verification checklist should not shorten with them — if anything, faster timelines make independent confirmation of the underlying evidence more valuable, not less.
🤝 Final Thoughts
Clinical trial evidence is the least-used and most revealing part of Indian pharmaceutical due diligence. It is public, it is specific, and it is hard to fake at scale — which is exactly what makes it useful. A supplier that can walk you through its SEC history, its open conditions, and its Ethics Committee traceability is demonstrating the same documentation discipline you are relying on for batch release.
When it comes to sourcing itself, documentation discipline should extend to your distribution chain. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory, which connects buyers with members whose regulatory standing has been reviewed.
For more information, contact IMSDA at contact@indiamedicine.org.
Sources: The Economic Times, “India may open doors to multinational pharma firms for first-in-human Phase I trials,” 12 November 2026; ETPharma, “India to Overhaul Drug Regulatory Norms to Attract Global Players,” 12 November 2026; New Drugs and Clinical Trials (Amendment) Rules, 2026, Ministry of Health and Family Welfare, notified January 2026; ICMR, “Advancing First-in-Human Phase 1 Clinical Trials in India: A Delphi Study on Regulatory Pathways and Opportunities,” released 20 May 2026; Union Budget 2026–27 (Bio Pharma Shakti). Framework and verification guidance are IMSDA editorial analysis.